On Monday, Berry Plastics Group Inc (NYSE:BERY)’s shares declined -4.03% to $29.07.
Berry Plastics Group, Inc. (BERY) declared the pricing of the private placement launched September 16, 2015 by one if its indirect, wholly owned auxiliaries (the “Issuer”). The Issuer will issue $400 million of second precedingity senior secured notes due 2022 (the “Notes”). The closing of the private placement offering is predictable to occur on or about October 1, 2015.
The Notes will bear interest at a rate of 6.00% payable semiannually, in cash in arrears, on April 15 and October 15 of each year, commencing April 15, 2016 and will mature on October 15, 2022.
Berry Plastics Group, Inc. manufactures and distributes plastic consumer packaging and engineered materials in North America and internationally. The company operates through four segments: Rigid Open Top, Rigid Closed Top, Engineered Materials, and Flexible Packaging.
Fitbit Inc (NYSE:FIT)’s shares dropped -4.18% to $36.03.
Fitbit, Inc., the leader in the connected health and fitness market, recently declared that it supports HIPAA compliance, enabling Fitbit Wellness to more effectively integrate with HIPAA-covered entities, counting corporate wellness partners, health plans and self-insured employers. The U.S. Health Insurance Portability and Accountability Act (HIPAA) is the primary U.S. law governing the security and privacy of personal health information used by health insurance plans and other covered entities.
Fitbit Inc. manufactures and provides wearable fitness-tracking devices worldwide. The company makes both wrist bands and clippable devices that monitor a user’s fitness activity by tracking the calories burned or distance covered.
At the end of Monday’s trade, Advaxis, Inc. (NASDAQ:ADXS)‘s shares dipped -11.60% to $12.19.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and the Gynecologic Oncology Group (GOG, now part of NRG Oncology), recently declared clinical data from Stage 1 of an ongoing two-stage Phase 2 study (GOG-0265) of Advaxis’s lead Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) who have progressed on at least one preceding line of systemic therapy. The Stage 1 data showed that treatment with axalimogene filolisbac resulted in a 38.5 percent 12-month overall survival rate in 26 patients.
Evaluation of safety data showed that Grade 1 or 2 adverse events occurred in 19 out of 26 patients (73 percent), with fatigue, chills and fever being the most common. Four patients (15 percent) practiced a Grade 3 adverse event (hypotension and cytokine release syndrome) and one patient (4 percent) practiced a Grade 4 adverse event (lung infection and sepsis). The results were presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting in Half Moon Bay, Calif. by Tom Herzog, M.D., Clinical Director at the University of Cincinnati Cancer Institute.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.
Lumenis Ltd (NASDAQ:LMNS), ended its Monday’s trading session with -0.95% loss, and closed at $13.51.
Lumenis Ltd. (LMNS), the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, declared the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Ongoing to innovate in the laser technology space, Lumenis’ UltraPulse CO2 laser platform is considered to be the industry gold standard solution for minimally invasive proceduresfor over three decades. Featuring superior precision and high-end performance technology, the UltraPulse DUO provides surgeons with the option to easily shift between free beam and fiber energy deliveries all within the same platform. This unique energy delivery combination allows for the superior precision needed to protect delicate tissue and the extended flexibility required for targeting difficult-to-reach anatomy.
Lumenis Ltd., together with its auxiliaries, develops and commercializes energy-based medical systems for use in minimally invasive procedures worldwide. It operates through three segments: Surgical, Ophthalmic, and Aesthetic.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
